Navigation Links
Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary
Date:7/30/2010

SAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology.

Conatus Pharmaceuticals is led by Steven J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The addition of Idun to Conatus continues our important work in liver disease and expands our therapeutic reach into oncology," said Dr. Mento.  "Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology."

Idun Pharmaceuticals was a privately-held biopharmaceutical company engaged in the discovery and development of drug candidates to control apoptosis. At the time of the acquisition by Pfizer, Idun had a Phase 2 drug candidate in liver disease (emricasan/IDN-6556), preclinical drug candidates including IDN-13389 for oncology, a development agreement with Abbott for an oncology drug candidate, and key intellectual property in the field of apoptosis.  Conatus' SVP Corporate Development, Jennifer Giottonini Cayer added, "We appreciate the contributions of Pfizer's colleagues on these potentially important drug candidates.  Conatus is excited to have the opportunity to work on these programs."  

Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. The lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
2. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
3. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
4. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
5. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
6. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
7. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):